- Barrons.com•11 hours ago
Despite Allergan’s robust drug pipeline and growing revenue and profits, its shares have fallen by a third from its all-time high of $340 in mid-2015 to Friday’s $230.47. The market’s disenchantment with this maker of products such as wrinkle-treatment Botox has more to do with industry issues and sentiment than company woes. Last April, investors bailed out after Pfizer’s (PFE) proposed $150 billion purchase of Allergan disintegrated, following opposition to tax aversions by the Obama administration.
- Investor's Business Daily•19 hours ago
Gilead's NASH drug is "clearly active and promising," but Intercept Pharmaceuticals remains one to two years ahead, RBC says.
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||230.20 x 800|
|Ask||233.20 x 2000|
|Day's Range||229.33 - 232.41|
|52wk Range||195.50 - 322.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.94|
|Avg Vol (3m)||3,297,413|
|Dividend & Yield||N/A (N/A)|